News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 12, 2024

Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3

Robert Gabbay, MD, PhD, discusses the early intervention at the asymptomatic stages of type 1 diabetes characterized by autoimmune antibodies and gradual blood sugar elevations.

Episodes in this series

Video 1 - "Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2"

EP. 1 Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2

Video 2 - "Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3"

EP. 2 Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3

Video 3 - "Identifying Risk to Enable Early Detection of Type 1 Diabetes "

EP. 3 Identifying Risk to Enable Early Detection of Type 1 Diabetes

Video 4 - "Challenges in Autoantibody Screening for Type 1 Diabetes"

EP. 4 Challenges in Autoantibody Screening for Type 1 Diabetes

Video 5 - "Strategies for Preventing Progression of Early-Stage Type 1 Diabetes"

EP. 5 Strategies for Preventing Progression of Early-Stage Type 1 Diabetes

Video 6 - "Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus"

EP. 6 Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus

Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"

EP. 7 Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Even After 6 Years, Disease Progression Impacts Survival in Mantle Cell Lymphoma

February 6th 2026

Acalabrutinib | Image Credit: © Сергей Шиманович-stocka.dobe.com.jpeg

Real-World Evidence Backs Acalabrutinib in CLL Care

ByMaggie L. Shaw

February 6th 2026

Debates at the International Stroke Conference 2026 centered on optimal treatment of ischemic stroke in the modern era. | Image credit: Aliaksandr Marko - stock.adobe.com

Is Less More After Thrombolysis? Debating Intensive Stroke Monitoring at ISC 2026

February 6th 2026

Dr Susan Vadaparampil

Linking Community Screening Programs to Cancer Centers Boosts Trial Diversity: Susan Vadaparampil, PhD, MPH

ByBrooke McCormick,Susan Vadaparampil, PhD, MPH

February 6th 2026

AJMC letter to the editor

Quality of Life: The Pending Outcome in Idiopathic Pulmonary Fibrosis

ByFranco Nicolae Grados Rodriguez

February 6th 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

5 Things to Know About the Oral GLP-1 Era

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text